Sertraline-Induced Stuttering in an Adolescent with Autism Spectrum Disorder
Abstract views: 339 / PDF downloads: 385
DOI:
https://doi.org/10.58600/eurjther2172Keywords:
stuttering, sertraline, autism, adolescent, Antidepressant agentsAbstract
There is also evidence that stuttering is caused by an adverse reaction to various medications. Antiepileptic drugs, antidepressants, antipsychotics, and methylphenidate have all been linked to drug-induced stuttering. The patient was 13 years old (male) and was diagnosed with autism spectrum disorder, attention deficit hyperactivity disorder, and mild mental retardation. The patient had language development and was able to form sentences of 4-5 words. Atomoxetine 50 mg/day and aripiprazole 15 mg/day treatment was used. Sertraline 50 mg/day treatment was initiated because of repeated questioning, order-symmetry compulsions and repetitive behaviors. Approximately one month after the initiation of sertraline treatment, the patient came for a follow-up visit and it was found that the compulsions of the patient had decreased, but one week after sertraline treatment, it was learned that the patient started to have word blocks, prolongation of words and repetitions during speech. No pathology was found in the examination, hemogram and biochemistry tests, brain MRI and EEG tests. After sertraline treatment was discontinued, the stuttering of the patient gradually decreased and improved within 2 weeks. Both serotonergic and dopaminergic effects of sertraline as well as autism spectrum disorder (white matter anomalies) are thought to contribute to sertraline-induced stuttering.
Metrics
References
Ekhart C, van Hunsel F, van Harten P, van Baarsen J, Yingying T, Bast B (2021) Drug-Induced Stuttering: Occurrence and Possible Pathways. Front Psychiatry 12:692568. https://doi.org/10.3389/fpsyt.2021.692568
Junuzovic-Zunic L, Sinanovic O, Majic B (2021) Neurogenic Stuttering: Etiology, Symptomatology, and Treatment. Med Arch 75:456-461. https://doi.org/10.5455/medarh.2021.75.456-461
Trenque T, Claustre G, Herlem E, Djerada Z, Trenque A, Morel A, Azzouz B (2019) Methylphenidate and stuttering. Br J Clin Pharmacol 85:2634-2637. https://doi.org/10.1111/bcp.14097
Nikvarz N, Sabouri S (2022) Drug-induced stuttering: A comprehensive literature review. World J Psychiatry 12:236-263. https://doi.org/10.5498/wjp.v12.i2.236
Metzger FL, Auer T, Helms G, Paulus W, Frahm J, Sommer M, Neef NE (2018) Shifted dynamic interactions between subcortical nuclei and inferior frontal gyri during response preparation in persistent developmental stuttering. Brain Struct Funct 223:165-182. https://doi.org/10.1007/s00429-017-1476-1
Maguire GA, Nguyen DL, Simonson KC, Kurz TL (2020) The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis. Front Neurosci 14:158. https://doi.org/10.3389/fnins.2020.00158
Asan O, Yaylaci ET, Okay IT, Goka E (2018) A case of stuttering due to olanzapine treatment. Dusunen Adam The Journal of Psychiatry and Neurological Sciences 31:405-408
Brady JP (1998) Drug-induced stuttering: a review of the literature. J Clin Psychopharmacol 18:50-54. https://doi.org/10.1097/00004714-199802000-00008
Stahl SM (2021) Stahl's essential psychopharmacology: neuroscientific basis and practical applications. Cambridge university press, Cambridge, UK
Sanchez C, Reines EH, Montgomery SA (2014) A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol 29:185-196. https://doi.org/10.1097/yic.0000000000000023
Kronfeld-Duenias V, Amir O, Ezrati-Vinacour R, Civier O, Ben-Shachar M (2016) The frontal aslant tract underlies speech fluency in persistent developmental stuttering. Brain Struct Funct 221:365-381. https://doi.org/10.1007/s00429-014-0912-8
Yang Q, Huang P, Li C, Fang P, Zhao N, Nan J, Wang B, Gao W, Cui LB (2018) Mapping alterations of gray matter volume and white matter integrity in children with autism spectrum disorder: evidence from fMRI findings. Neuroreport 29:1188-1192. https://doi.org/10.1097/wnr.0000000000001094
Downloads
Published
How to Cite
License
Copyright (c) 2024 European Journal of Therapeutics
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.